Pediatric and young adult renal cell carcinoma

Satyajit Ray; Robert Jones; Kathy Pritchard-Jones; Kristina Dzhuma; Marry van den Heuvel-Eibrink; Godelieve Tytgat; Justine van der Beek; Grenville Oades; Dermot Murphy

doi:10.1002/pbc.28675

Pediatric and young adult renal cell carcinoma

Satyajit Ray, Robert Jones, Kathy Pritchard-Jones, Kristina Dzhuma, Marry van den Heuvel-Eibrink, Godelieve Tytgat, Justine van der Beek, Grenville Oades, Dermot Murphy

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel recenseren › peer review

12 Citaten (Scopus)

Samenvatting

Renal cell carcinoma (RCC) is rare in children but is the most common renal tumor in adults. Pediatric RCC has different clinical characteristics, histopathology, and treatment compared with adult disease. Databases were reviewed from inception to February 2020, identifying 32 publications pertaining to 350 patients under 27 years. Surgery is the cornerstone for cure in localized RCC. Lymph node dissection remains controversial. Conventional radiotherapy has no curative role in RCC; similarly, conventional chemotherapy has not proven to be effective in large cohorts. Pediatric metastatic RCC has a poor outlook. There are no published prospective studies demonstrating which adjuvant therapy could improve outcome. Sunitinib, a tyrosine kinase inhibitor, is recommended in this group despite limited evidence. This review provides an overview for pediatric RCC, including the evolving role of precision medicine.

Originele taal-2	Engels
Artikelnummer	e28675
Tijdschrift	Pediatric Blood and Cancer
Volume	67
Nummer van het tijdschrift	11
DOI's	https://doi.org/10.1002/pbc.28675
Status	Gepubliceerd - 1 nov. 2020

Toegang tot document

10.1002/pbc.28675

Citeer dit

@article{fa93194235ee4fc59752d548cfe96ee0,

title = "Pediatric and young adult renal cell carcinoma",

abstract = "Renal cell carcinoma (RCC) is rare in children but is the most common renal tumor in adults. Pediatric RCC has different clinical characteristics, histopathology, and treatment compared with adult disease. Databases were reviewed from inception to February 2020, identifying 32 publications pertaining to 350 patients under 27 years. Surgery is the cornerstone for cure in localized RCC. Lymph node dissection remains controversial. Conventional radiotherapy has no curative role in RCC; similarly, conventional chemotherapy has not proven to be effective in large cohorts. Pediatric metastatic RCC has a poor outlook. There are no published prospective studies demonstrating which adjuvant therapy could improve outcome. Sunitinib, a tyrosine kinase inhibitor, is recommended in this group despite limited evidence. This review provides an overview for pediatric RCC, including the evolving role of precision medicine.",

keywords = "pediatrics, renal cell carcinoma, targeted therapy, treatment",

author = "Satyajit Ray and Robert Jones and Kathy Pritchard-Jones and Kristina Dzhuma and {van den Heuvel-Eibrink}, Marry and Godelieve Tytgat and {van der Beek}, Justine and Grenville Oades and Dermot Murphy",

note = "Publisher Copyright: {\textcopyright} 2020 Wiley Periodicals LLC",

year = "2020",

month = nov,

day = "1",

doi = "10.1002/pbc.28675",

language = "English",

volume = "67",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "11",

}

TY - JOUR

T1 - Pediatric and young adult renal cell carcinoma

AU - Ray, Satyajit

AU - Jones, Robert

AU - Pritchard-Jones, Kathy

AU - Dzhuma, Kristina

AU - van den Heuvel-Eibrink, Marry

AU - Tytgat, Godelieve

AU - van der Beek, Justine

AU - Oades, Grenville

AU - Murphy, Dermot

PY - 2020/11/1

Y1 - 2020/11/1

N2 - Renal cell carcinoma (RCC) is rare in children but is the most common renal tumor in adults. Pediatric RCC has different clinical characteristics, histopathology, and treatment compared with adult disease. Databases were reviewed from inception to February 2020, identifying 32 publications pertaining to 350 patients under 27 years. Surgery is the cornerstone for cure in localized RCC. Lymph node dissection remains controversial. Conventional radiotherapy has no curative role in RCC; similarly, conventional chemotherapy has not proven to be effective in large cohorts. Pediatric metastatic RCC has a poor outlook. There are no published prospective studies demonstrating which adjuvant therapy could improve outcome. Sunitinib, a tyrosine kinase inhibitor, is recommended in this group despite limited evidence. This review provides an overview for pediatric RCC, including the evolving role of precision medicine.

AB - Renal cell carcinoma (RCC) is rare in children but is the most common renal tumor in adults. Pediatric RCC has different clinical characteristics, histopathology, and treatment compared with adult disease. Databases were reviewed from inception to February 2020, identifying 32 publications pertaining to 350 patients under 27 years. Surgery is the cornerstone for cure in localized RCC. Lymph node dissection remains controversial. Conventional radiotherapy has no curative role in RCC; similarly, conventional chemotherapy has not proven to be effective in large cohorts. Pediatric metastatic RCC has a poor outlook. There are no published prospective studies demonstrating which adjuvant therapy could improve outcome. Sunitinib, a tyrosine kinase inhibitor, is recommended in this group despite limited evidence. This review provides an overview for pediatric RCC, including the evolving role of precision medicine.

KW - pediatrics

KW - renal cell carcinoma

KW - targeted therapy

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85089997981&partnerID=8YFLogxK

U2 - 10.1002/pbc.28675

DO - 10.1002/pbc.28675

M3 - Review article

C2 - 32869954

AN - SCOPUS:85089997981

SN - 1545-5009

VL - 67

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 11

M1 - e28675

ER -

Pediatric and young adult renal cell carcinoma

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit